VYLEESI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the ...
The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients WALTHAM, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- ...
Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform CRANBURY, N.J., Aug. 7, 2023 /PRNewswire/ -- ...
With the FDA go-ahead for Vyleesi (bremelanotide) in generalized hypoactive sexual desire disorder (HSDD), Amag Pharmaceuticals Inc.'s comparison of prospects for the compound to those of depression ...
CRANBURY, N.J., July 26, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform "We are excited to partner with UpScriptHealth, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results